LCSG - formerly LCS Golf (fka LCSG)

[jmhollen]

FYI: Many of the new medicines developed here in the USA come from extracts from tropical plants, and 'strange critters', in Central and South America and Africa, the ocean, etc. If you ever travel through Panama, you should make a point to go to the Baro Colorado Island research station in the middle of the Canal - they do a lot of that kind of work.

Also, a new method for healing broken bones is to insert a segment of a special coral (..found somewhere in the South Pacific..) as I recall. The coral is pourous, so the new bone grows in, around and through it - and eventually the coral dissolves, leaving only the new strong bone.

Like Anna Rosannadanna used to say, "..You know, it's always sumpthin'......".

Have a nice day.

John

[jmhollen]

"...Nervous...", ha ha ha ha ha... Sounds like the symptom of a different mallady; ....one too many Hillary, Boxer and Streisand cartoons, perhaps...!! DYO effective DD (x2) is always a prerequisite with Penny Stocks though.

The asian fellow and the therapy seemed to be legit, from what I read about it. I also have a cousin who is an MD with a practice in Accupuncure in Chicago; so many Chinese medical practices and medicines obviously work for the Chinese and us.

I think the LCSG deal has failed to succeed because of the involvement of some overly-greedy financiers, etc.

John

[marks]

Regarding tubercin, I'm a bit nervous when it sounds to good to be true?

[jmhollen]

A little late for them to figure all that out, it would seem.....

LCSG 0.12 -0.06 (-33.33%) 0.12 0.13 793,700


John

.

[jmhollen]

LCS Golf Inc. Announces Termination of Letter of Intent With T-19 Inc.

WEST PALM BEACH, Fla., May 2, 2002 (BUSINESS WIRE) -- LCS Golf (OTCBB:LCSG) announced today that it is not preceding under the letter of intent to effect the merger with T-19 Corporation.

Based upon the completion of Due Diligence, the company will no longer continue talks with T-19 Corporation.

The financing with the Pickens Group has been cancelled.

The company is committed to exploring other opportunities and financing.

CONTACT: TI Communications, Naples, Fla. Jeff Schuler, 1-888-753-7080

[jmhollen]

Prestigious Journal Publishes Case Study Highlighting T-19

HONOLULU--(BW HealthWire)--April 4, 2002--T-19 Incorporation (which has entered into a letter of intent to be acquired by LCS Golf) (OTCBB:LCSG) announced today that the International Journal of Dermatology has published a case study detailing the use of Tubercin.

The International Journal of Dermatology, published by Blackwell Science, Ltd. of London, England, (Vol 41:1 paper 1388) printed the case study written by Tubercin inventor, Dr. Tai-Ho Chung in its January 2002 edition. The article is entitled, `Regression of an acral lentiginous melanoma with an immunotherapy using a Mycobacterium tuberculosis-extracted polysaccharide complex (Tubercin).'

The case study documented the successful treatment of Acral Lentiginous Melanoma on a 77-year-old woman with Tubercin. The woman was diagnosed with terminal Acral Lentiginous Melanoma on her arm and was given three to four months to live if the arm was not amputated. The woman refused amputation and sought out Dr. Chung to administer Tubercin and began her treatment on December 24, 1999. On December 28, 2000 an official biopsy was performed and the woman was declared cancer free. The entire article can be reviewed at: http://www.tubercin.com.

LCS Golf President Michael Mithcell, M.D. stated, "The publication of this case study in a well known and well respected medical journal is obviously very good news. The successful treatment outlined in the article will help increase the credibility of the product and will likely create additional demand for the T-19 nasal spray."

Earlier this week, LCS Golf announced that the Pickens Group and its CEO, Michael O. Pickens had purchased 2,000,000 shares of LCSG stock for $1,000,000. The proceeds from this equity investment will be used to complete the acquisition of T-19 Incorporation.

CONTACT: T-19 Incorporation, Honolulu
Eric Schopfer, 866/523-5800

.

[jmhollen]

Pickens Group Makes Equity Investment in LCS Golf

WEST PALM BEACH, Fla., Apr 2, 2002 (BW HealthWire) -- Pickens makes investment in LCS Golf (OTC:LCSG).

Pickens Group has purchased 2,000,000 shares of restricted 144 stock for $1,000,000. LCSG will use the proceeds from the equity investment to complete the acquisition of T-19 Incorporated.

Michael O. Pickens, son of T. Boone Pickens and CEO of Pickens Group, said "T-19 is a very exciting acquisition for LCS Golf, and I am very pleased to be part of this transaction. Dr. Michael Mitchell and his team are great to work with and I look forward to an extremely successful expansion of T-19." The Pickens Group invests debt/equity capital in private/public companies and manages the group of M3 hedge funds.

T-19 Inc., will become a wholly owned subsidiary of LCS Golf Inc.

T-19 holds U.S. (http://patft.uspto.gov/netacgi/tubercin) and Foreign patents along with worldwide distribution rights for T-19. (http://www.T-19.com) T-19 is a Nasal Spray comprised of a natural compound called Tubercin (www.tubercin.com). The T-19 Nasal Spray will be marketed worldwide, as an immune stimulant, through traditional retail distribution networks. T-19 may enhance the human immune system and help improve overall health. T-19 is natural and has no known adverse side effects.

Mike Pickens and Dr. Michael D. Mitchell will be working together with LCS to insure the successful future of T-19 Incorporated.

LCS Golf CEO Michael D. Mitchell M.D. stated, "It gives me great satisfaction that the Pickens group believes as strongly as I do in this merger between LCS Golf and T-19 Incorporated (Tubercin). I look forward to working with Mike Pickens and the Pickens Group.

T-19 (Tubercin) is a neutraceuticle product, it is ingested as a nasal spray and helps support a healthy immune system.

The Pickens Group LLC has been very successful in presenting companies to the financial community and this unique opportunity gives LCS Golf, (OTC:LCSG) not only a strong investor but also a very strong circle of influence to open doors as we launch our products," said Dr. Michael Mitchell, CEO of LCS Golf.

Dr. Ronald Shinn, president and CEO of T-19 Incorporation, comments, "With the addition of the Pickens Group we are now a well rounded company and we will be able to move product to market and build a successful company."

CONTACT: T-19 Incorporated, Honolulu Eric Schopfer, 866/523-5800

.

[jmhollen]

T-19 Inc. Proud to Announce Tubercin Inventor and Scientific Advisor Dr. Tai-Ho Chung Ph.D. M.D. Has Been Reappointed World Health Organization Immunological Research Director

HONOLULU--(BW HealthWire)--March 22, 2002--T-19 Incorporated is proud to announce that Tubercin inventor and scientific advisor Dr. Tai-Ho Chung Ph.D. M.D. has been reappointed Director of the World Health Organization (WHO) Collaborating Centre for Immunological Research on the Prevention and Control of Viral Hepatitis and its Related Disease.

T-19 has entered into a Letter of Intent to be acquired by LCS Golf Inc (OTCBB:LCSG). LCS Golf President Michael Mitchell M.D. says, This appointment furthers the credibility and our excitement concerning this pending acquisition.

Over two thousand stage 3 and 4 cancer patients have been treated with an injectable version of Tubercin under strict clinical settings in South Korea at the oldest and very prestigious university hospital, Kyungpook National University Medical School, in Taegu, Korea. Today approximately 40% of these 2000 terminal Cancer patients were positively impacted and a significant number has remained cancer free within a 20 year duration. Dr. Tai-Ho Chung, the inventor of Tubercin T-5, has published his findings over the last seventeen years in Korean Medical Journals. Dr. Tai-Ho Chung was the former Medical School dean and is currently the Director of the World Health Organization (WHO) Collaborating Centre for Immunological Research on the Prevention and Control of Viral Hepatitis and its Related Disease situated at the Kyungpook National University, Taegu, Korea.

T-19 Incorporated is preparing a version of Tubercin called T-19 which is to be ingested as a nasal spray.

More information can be found at: http://www.tubercin.com.


CONTACT: T-19 Incorporated, Honolulu
Eric Schopfer, 866/523-5800

.

[jmhollen]

Shinn Capital Group Grants Two Licenses 18 Mar 2002, 1:46pm ET

HONOLULU--(BUSINESS WIRE)--March 18, 2002--Shinn Capital Group, Inc. (SCG), a Hawaii based corporation, recently granted two licenses to work with its immunostimulant Tubercin. SCG has the exclusive worldwide rights for this compound developed and administered in South Korea for the last 14 years.

It is the intent of SCG and the licensees to bring Tubercin, an immunostimulant that combats diseases such as Cancer, Aids and Arthritis, to the world markets through a variety of delivery methods. Tubercin was invented by Dr. Tai-Ho Chung of Kyungpook National University Medical School, Taegu, Korea. Tubercin is patented in the US, Japan and Korea (US Patent 6,274,356).

T-19 Incorporated (OTCBB:LCSG) was granted a license to develop products for the worldwide retail and holistic marketplaces as well as the implementation of off shore clinics; and is currently working on a Nasal Spray that appears promising and should be available in the immediate future.

Hard-To-Treat Diseases Inc. (HTTD), a wholly owned subsidiary of Gatlin Holdings, Inc. (OTCBB:GTNH) was granted a license to develop products for the Federal Drug Administration regulated marketplace as well as seek FDA approval.

Shinn Capital Group, Inc. is very supportive of both HTTD and T-19 in their missions to make Tubercin available as quickly as possible to those who seek help. SCG is a privately held investment group with close ties to the South Korean medical community.

CONTACT: SCG, Honolulu

Ronald Shinn, 808/523-5800 or toll-free 866/523-5800

.

[jmhollen]

LCS Golf, Inc. Enters Into a Letter of Intent to Acquire T-19 Inc.

WEST PALM BEACH, Fla., Feb 20, 2002 (BW HealthWire) -- LCS Golf (OTCBB:LCSG) announced today that it has entered into a Letter of Intent agreement to acquire at least 90% of the outstanding privately held shares of T-19 Incorporated based in Honolulu, Hawaii, in an all stock transaction.

At the completion of the acquisition, T-19 shareholders will own the majority of LCS GOLF INC.

T-19 Incorporated holds the worldwide distribution rights for T-19. (http://www.T-19.com) T-19 is a Nasal Spray comprised of a natural compound called Tubercin, which enjoys US and other foreign patents. The T-19 Nasal Spray will be marketed worldwide through traditional retail distribution networks as a holistic treatment. T-19 may enhance the human immune system and help improve overall health. T-19 (http://www.Tubercin.com) is natural and has no known adverse side effects.

Dr. Ronald Shinn President and CEO of T-19 incorporated comments, "We are delighted with LCS Golf and Dr. Michael Mitchell for furthering our capabilities with their expertise and resources to help bring T-19 to the market."

CONTACT: T-19 Incorporated, Honolulu Eric Schopfer, 866/523-5800

.